Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

$248.68 +1.17 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$250.12 +1.44 (+0.58%)

As of 05:28 PM Eastern

Compare

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
5

Buy
19

Based on 24 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 5 have given a hold rating, 17 have given a buy rating, and 2 have given a strong buy rating for ALNY.

Consensus Price Target

$376.67
51.47% Upside

According to the 24 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $376.67. The highest price target for ALNY is $566.00, while the lowest price target for ALNY is $256.00. The average price target represents a forecasted upside of 51.47% from the current price of $248.68.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALNY Analyst Ratings Over Time

Type	Current Forecast 9/11/25 to 9/11/26	1 Month Ago 8/12/25 to 8/12/26	3 Months Ago 6/13/25 to 6/13/26	1 Year Ago 9/11/24 to 9/11/25
Strong Buy	2 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	16 Buy rating(s)	18 Buy rating(s)	23 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$376.67	$396.72	$463.13	$421.28
Forecasted Upside	51.47% Upside	77.15% Upside	63.74% Upside	-10.09% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals Stock vs. The Competition

Type	Alnylam Pharmaceuticals	Healthcare Companies	Broader Market
Consensus Rating Score	2.88	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	52.18% Upside	906.46% Upside	17.26% Upside
News Sentiment Rating	Positive News See Recent ALNY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/8/2026	Jefferies Financial Group 3 of 5 stars	Faisal Khurshid Not Rated	Boost Target	Hold	$230.00 ➝ $260.00	-0.31%
9/2/2026	HC Wainwright 4 of 5 stars	Patrick R. Trucchio 5 of 5 stars	Reiterated Rating	Buy	$455.00	+84.88%
8/31/2026	Sanford C. Bernstein 3 of 5 stars	Jeffrey Walch Not Rated	Reiterated Rating	Buy
8/31/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
8/31/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Lebowitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
8/14/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derek Archila Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$316.00 ➝ $256.00	+14.69%
8/4/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$410.00 ➝ $315.00	+45.81%
8/3/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Joseph Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$380.00 ➝ $340.00	+57.03%
8/3/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Martin Auster Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$420.00	+104.36%
8/3/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$527.00 ➝ $450.00	+118.96%
Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
7/31/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C-) ➝ Hold (C)
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$445.00 ➝ $350.00	+72.34%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$400.00 ➝ $375.00	+84.65%
7/31/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ulz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$400.00 ➝ $300.00	+48.01%
7/31/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$500.00 ➝ $350.00	+72.59%
7/31/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$444.00 ➝ $318.00	+56.37%
7/31/2026	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keay Nakae Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$425.00	+106.83%
7/30/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$510.00 ➝ $357.00	+76.83%
7/14/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$460.00 ➝ $410.00	+46.17%
2/17/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
2/17/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Whitney Ijem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$415.00 ➝ $429.00	+36.62%
12/15/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mani Foroohar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Perform	$370.00 ➝ $351.00	-10.26%
10/31/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Edward Tenthoff Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$449.00 ➝ $489.00	+8.21%
9/16/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$504.00 ➝ $566.00	+22.67%
9/11/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Liisa Bayko Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$280.00 ➝ $515.05	+9.93%
8/4/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/1/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Greg Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Outperform	$342.00 ➝ $450.00	+12.00%
8/1/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$403.00 ➝ $550.00	+38.02%
3/31/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$353.00	+31.49%
3/21/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
10/11/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral	$220.00 ➝ $220.00	-21.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:32 PM ET.

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 9, 2026. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

Alnylam Pharmaceuticals, Inc. recently reported strong financial performance in its latest quarter, with revenue of $1.29 billion, representing a 66.9% year-over-year increase, and earnings per share of $1.84, which exceeded the consensus estimate of $1.63 by $0.21, demonstrating robust commercial execution and profitability with a net margin of 15.26%.
The company maintains a strong balance sheet with a quick ratio of 2.99 and a current ratio of 3.05, indicating ample liquidity to support its operations and R&D pipeline, while its debt-to-equity ratio of 0.75 suggests a manageable leverage level for a biopharmaceutical firm.
Wall Street analysts maintain a consensus rating of "Moderate Buy" with an average price target of $382.96, which implies significant upside potential from the current stock price of $258.00, reflecting continued institutional confidence in the company's long-term growth trajectory.
Institutional investor interest remains high, with 92.97% of the stock owned by institutional investors, and recent filings show significant new positions or increased stakes by major funds such as Norges Bank, Legal & General Group Plc, and AQR Capital Management LLC, signaling broad market validation.
The company's RNA interference therapeutics portfolio, including marketed products like ONPATTRO and AMVUTTRA, continues to drive durable disease modification, supported by strategic collaborations with major pharmaceutical companies like Regeneron and Roche to expand its reach into new therapeutic areas.

Alnylam Pharmaceuticals
Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

The current stock price of $258.00 is significantly below the 52-week high of $495.55 and the 200-day simple moving average of $290.47, indicating a substantial recent decline in valuation and potential ongoing downward pressure on the share price.
Insider selling activity has been consistent, with 67 sales recorded in the past six months and zero purchases, including recent sales by CEO Yvonne Greenstreet and other executives, which may signal a lack of internal conviction or a desire to monetize gains at current price levels.
Several major brokerage firms have recently lowered their price targets, such as Royal Bank of Canada reducing its target from $445.00 to $350.00 and Needham & Company LLC cutting its target from $510.00 to $357.00, suggesting that analysts are becoming more conservative about the company's near-term growth prospects.
The company's P/E ratio of 47.96 is relatively high, which may limit upside potential if earnings growth slows, and the stock's beta of 0.31, while indicating lower volatility than the market, also suggests it may underperform in strong bull markets compared to higher-beta peers.
Short interest, while modest at 3.6% of the float, has shown periods of increase, with days to cover reaching up to 5.78 in recent months, indicating that some market participants are actively betting against the stock, which could create additional selling pressure.

ALNY Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $376.67, with a high forecast of $566.00 and a low forecast of $256.00.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 5 hold ratings, 17 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.

According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 51.47% based on their 12-month stock forecasts.

Over the previous 90 days, Alnylam Pharmaceuticals's stock had 4 upgrades by analysts.

Alnylam Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Chardan Capital, Citigroup, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Raymond James Financial, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, Truist Financial, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Alnylam Pharmaceuticals more than other "healthcare" companies. The consensus rating for Alnylam Pharmaceuticals is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ALNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Alnylam Pharmaceuticals Recommendations

MarketBeat monitors more than a dozen sources for Alnylam Pharmaceuticals analyst ratings, with the most recent rating issued on 9/8/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ALNY Analyst Ratings Over Time

ALNY Analyst Recommendations By Month

ALNY Price Targets by Month

Alnylam Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

Alnylam Pharmaceuticals
Bull Case

Alnylam Pharmaceuticals
Bear Case

ALNY Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Alnylam Pharmaceuticals Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ALNY Analyst Ratings Over Time

ALNY Analyst Recommendations By Month

ALNY Price Targets by Month

Alnylam Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

Alnylam Pharmaceuticals Bull Case

Alnylam Pharmaceuticals Bear Case

ALNY Forecast - Frequently Asked Questions

What is Alnylam Pharmaceuticals' forecast for 2026?

Should I buy or sell Alnylam Pharmaceuticals stock right now?

Does Alnylam Pharmaceuticals's stock price have much upside?

Has Alnylam Pharmaceuticals been upgraded by Wall Street analysts recently?

What analysts cover Alnylam Pharmaceuticals?

Do Wall Street analysts like Alnylam Pharmaceuticals more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Alnylam Pharmaceuticals Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Alnylam Pharmaceuticals
Bull Case

Alnylam Pharmaceuticals
Bear Case